Barclays analyst Saket Kalia maintains Tyler Technologies (NYSE:TYL) with a Equal-Weight and lowers the price target from $410 to $400.
Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry
Amidst today’s fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct…